Related Experiment Video
Updated: May 16, 2025
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.2K
[Rare cause of recurrent hypoglycemia].
Ifigeneia Barmpa1, Apostolos Chatzitomaris1, Eva Maria Lüngen1
1Klinik für Endokrinologie, Diabetologie und Geriatrie, Zentrum für Innere Medizin, Klinikum der Landeshauptstadt Stuttgart gKAöR Katharinenhospital, Stuttgart, Deutschland.
Innere Medizin (Heidelberg, Germany)
|April 1, 2025
Summary
Non-islet cell tumor hypoglycemia (NICTH) is a rare condition caused by excess insulin-like growth factor 2. Oral prednisolone was effective for a patient with progressing NICTH when surgery was not an option.
Area of Science:
- Endocrinology
- Oncology
- Metabolic Disorders
Background:
- Non-islet cell tumor hypoglycemia (NICTH) is a rare endocrine disorder.
- It results from excessive secretion of insulin-like growth factor 2 (IGF-2) or pro-IGF-2.
- Doege-Potter syndrome is a related term, often associated with thoracic tumors.
Purpose of the Study:
- To describe a case of NICTH with tumor progression.
- To evaluate treatment options for NICTH when surgery is not feasible.
Main Methods:
- A patient with NICTH and tumor progression was treated with oral prednisolone.
- The patient's condition was monitored during treatment.
Main Results:
- Tumor progression was observed over a short period.
- Oral prednisolone therapy was initiated and appeared effective.
- Diazoxide and octreotide were deemed not recommended for this condition.
Conclusions:
- NICTH requires careful management, especially when surgical debulking is not possible.
- Prednisolone may be a viable oral treatment option for managing NICTH.
- Specific medications like diazoxide and octreotide are not advised for NICTH.
More Related Videos
Related Concept Videos
01:15Hypoglycemia and Glucagon
143
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
143
01:22Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
01:20Pathophysiology of Diabetes
822
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
822
01:22Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
01:06Oral Hypoglycemic Agents: Glinides
114
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
114
01:27Glucose Transporters
22.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.2K